Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Nov 2022
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms STARTS-1
- Sponsors Pfizer; Pfizer Japan
- 14 Mar 2017 New trial record